BELL vs. RUA, SUN, MHC, DEMG, NIOX, SN, MXCT, EKF, CREO, and IUG
Should you be buying Belluscura stock or one of its competitors? The main competitors of Belluscura include RUA Life Sciences (RUA), Surgical Innovations Group (SUN), MyHealthChecked (MHC), Deltex Medical Group (DEMG), NIOX Group (NIOX), Smith & Nephew (SN), MaxCyte (MXCT), EKF Diagnostics (EKF), Creo Medical Group (CREO), and Intelligent Ultrasound Group (IUG). These companies are all part of the "medical devices" industry.
Belluscura vs. Its Competitors
Belluscura (LON:BELL) and RUA Life Sciences (LON:RUA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation, dividends and community ranking.
RUA Life Sciences has higher revenue and earnings than Belluscura. RUA Life Sciences is trading at a lower price-to-earnings ratio than Belluscura, indicating that it is currently the more affordable of the two stocks.
RUA Life Sciences has a net margin of -65.72% compared to Belluscura's net margin of -1,030.73%. RUA Life Sciences' return on equity of -26.38% beat Belluscura's return on equity.
Belluscura and RUA Life Sciences both received 0 outperform votes by MarketBeat users.
6.3% of Belluscura shares are owned by institutional investors. Comparatively, 26.0% of RUA Life Sciences shares are owned by institutional investors. 56.3% of Belluscura shares are owned by insiders. Comparatively, 51.3% of RUA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Belluscura's average media sentiment score of 0.00 equaled RUA Life Sciences'average media sentiment score.
Belluscura has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, RUA Life Sciences has a beta of 1.21, indicating that its share price is 21% more volatile than the S&P 500.
Summary
RUA Life Sciences beats Belluscura on 9 of the 11 factors compared between the two stocks.
Get Belluscura News Delivered to You Automatically
Sign up to receive the latest news and ratings for BELL and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Belluscura Competitors List
Related Companies and Tools
This page (LON:BELL) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy BELL Stock Free BELL Stock Alerts